BMN 701
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$120,996
Transactions
19
Doctors
6
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $120,996 | 19 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $105,056 | 13 | 86.8% |
| Education | $15,941 | 6 | 13.2% |
Payments by Type
Research
$105,056
13 transactions
General
$15,941
6 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease -INSPIRE Study | BioMarin Pharmaceutical Inc. | $102,056 | 0 |
| A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease | BioMarin Pharmaceutical Inc. | $3,000 | 0 |
Top Doctors Receiving Payments for BMN 701
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Evansville, IN | $105,056 | 13 |
| , MD | Pediatric Cardiology | Gainesville, FL | $2,657 | 1 |
| , M.D., PH.D | Clinical Biochemical Genetics | San Diego, CA | $2,657 | 1 |
| , MD | Neurology | Columbus, OH | $2,657 | 1 |
| , M.D | Pediatric Rehabilitation Medicine | Sacramento, CA | $2,657 | 1 |
| , M.D | Pediatric Pulmonology | Oakland, CA | $2,657 | 1 |
| , M.D | Neurology | Kansas City, KS | $2,657 | 1 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $120,996
Product Information
- Type Biological
- Total Payments $120,996
- Total Doctors 6
- Transactions 19
About BMN 701
BMN 701 is a biological associated with $120,996 in payments to 6 healthcare providers, recorded across 19 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2017. In 2017, $120,996 was paid across 19 transactions to 6 doctors.
The most common payment nature for BMN 701 is "Unspecified" ($105,056, 86.8% of total).
BMN 701 is associated with 2 research studies, including "Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease -INSPIRE Study" ($102,056).